Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-08-15
2006-08-15
Campell, Bruce R. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07091175
ABSTRACT:
A novel angiogenesis drug which can be clinically used for therapies of human or the like is disclosed. The angiogenesis drug according to the present invention comprises a peptide as an effective component, which has a prescribed amino acid sequence and has an angiogenesis action.
REFERENCES:
patent: 6509026 (2003-01-01), Ashkar et al.
patent: 2000-300263 (2000-10-01), None
patent: WO 91/05802 (1991-05-01), None
patent: WO 99/08730 (1999-02-01), None
patent: WO 00/63236 (2000-10-01), None
patent: WO 01/71358 (2001-09-01), None
Mogi, et al., Circulation, 2000, 102, 65.
Yokosaki, et al., The Journal of Biological chemistry, 1999, 274, 36328-34.
Smith, et al., Experimental Cell Research, 1998, 242, 351-360.
Myles, et al., Journal of Biomaterials Science, 2000, 11, 69-86.
Kiyoshi Nokihara et al.; Peptide Science 2000: T. Shioiri (Ed.); The Japanese Peptide Society (2001); pp. 373-376.
Masayuki Okazaki et al.; Dentistry in Japan; vol. 37; Mar. 2001; pp. 95-100.
Hamada Yoshinosuke
Matsuura Nariaki
Nokihara Kiyoshi
Takahashi Junzo
Birch & Stewart Kolasch & Birch, LLP
Campell Bruce R.
Gudibande Satyanarayana R.
LandOfFree
Angiogenesis drugs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Angiogenesis drugs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Angiogenesis drugs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3665937